Retatrutide is promising, but its still proving itself
Published research, receptor overlap risks, and what clinical data shows
This window is sufficient to observe early changes in body composition and GH axis responsiveness
otherwise 100,- Zone 1 (EU) including Switzerland and United Kingdom (GB): Belgium, Bulgaria, Denmark (except Faroe Islands, Greenland), Estonia, Finland (except land Islands), France (except overseas territories and departments), Greece (except Mount Athos), United Kingdom (GB, except Channel Islands), Ireland, Italy (except Livigno and Campione d'Italia), Croatia, Latvia, Lithuania, Luxembourg, Malta, Monaco, Netherlands (except non-European territories), Austria, Poland, Portugal, Romania, Sweden, Slovakia, Slovenia, Spain (except Canary Islands, Ceuta + Melilla), Czech Republic, Hungary, Cyprus/Republic (except northern part), including Switzerland Zone 2 (Europe excluding the EU): land Islands (Finland), Andorra, Albania, Armenia, Azerbaijan, Mount Athos (GR), Bosnia and Herzegovina, Campione d'Italia (IT), Ceuta (E), Faroe Islands (DK), Georgia, Gibraltar (GB), Greenland (DK), Guernsey (GB), Iceland, Jersey (GB), Canary Islands (E), Kazakhstan , Kosovo (Serbian province), Liechtenstein, Livigno (IT), Macedonia, Melilla (E), Moldova (Republic), Montenegro (Republic), Norway, Russian Federation, San Marino, Serbia (Republic), Turkey, Ukraine, Vatican City, Belarus, Cyprus/Republic (northern part) Zone 3 (World): Egypt, Algeria, Bahrain, Iran, Iraq, Israel, Yemen, Jordan, Canada, Qatar, Kuwait, Lebanon, Libya, Morocco, Oman, Saudi Arabia, Syria Tunisia, USA, United Arab Emirates Zone 4 (Rest of the world): All countries and territories not assigned to Zones 1, 2 or 3
